Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
|First Received Date ICMJE||September 30, 2005|
|Last Updated Date||April 22, 2012|
|Start Date ICMJE||November 2004|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE
||To determine the overall clinical response rate of weekly Topotecan and Taxotere in women with recurrent ovarian, primary peritoneal, endometrial and uterine cancers|
|Original Primary Outcome Measures ICMJE
||To determine the overall clinical response rate of weekly Topotecan and Taxotere in women with recurrent ovarian, primary peritoneal, endometrial and uterine cancers.|
|Change History||Complete list of historical versions of study NCT00231855 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers|
|Official Title ICMJE||Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal, Endometrial and Uterine Cancers|
The primary aim of this study is:
The secondary aims of this study are:
Endometrial carcinoma is the most common gynecologic cancer, accounting for 6,500 deaths in 2002 in the United States. There has been a 128% increase in endometrial cancer deaths over the past decade mainly due to recurrences. Although primary surgery with or without adjuvant therapy can cure most patients, effective therapy for those patients with advanced or recurrent disease is needed. Due to the advanced age of this patient population and associated medical comorbidities, these patients are not always ideal candidates for experimental therapies exploring dose intensity or toxic agents. Treatment options for advanced or recurrent disease are limited. Cytotoxic therapy has made little impact on survival.
Recent data has demonstrated efficacy of Topotecan in advanced or recurrent endometrial cancer. A Phase II trial performed primarily by the New York Gynecologic Oncology Group through ECOG found Topotecan to be an active first line treatment for metastatic or recurrent endometrial cancer. The overall response rate was 20% with 3/40 patients complete responders. A Phase II trial by the Gynecologic Oncology Group (GOG) of 29 patients with advanced or recurrent endometrial cancer reported a 10% overall response rate to 5-day intravenous Topotecan. However, 55% of patients had stable disease. Reported side effects were mainly hematologic, specifically, neutropenia and thrombocytopenia. Finkler and Holloway reported a phase I/II trial using weekly Topotecan in recurrent endometrial cancer. 23% of patients had partial response to therapy, with a decrease in grade 4 neutropenia and thrombocytopenia compared to the 5-day infusion. In a pilot study examining the role of 5-day Topotecan in uterine papillary serous carcinoma (UPSC), Chambers et al. report 11 of 12 patients who received Topotecan as front-line therapy to be disease-free at 13 months median follow-up. Anemia and neutropenia were managed effectively with hematopoietic stimulating factors.
Taxanes have also been reported to be effective in the treatment of advanced and recurrent endometrial cancer. Endometrial cancer cell lines have demonstrated sensitivity to paclitaxel. Response rates of 35%-37% have been reported in two separate phase II trials. Günthert et al., reported a complete response to Taxotere in a patient with recurrent endometrial cancer.
Taxotere is an agent well documented in the management of advanced ovarian cancer, with a response rate of approximately 30% in platinum-refractory patients. Taxotere has also demonstrated clinical response in patients classified as paclitaxel-refractory, confirming an incomplete cross-resistance between these two agents. Based on these data, there is reason to believe that the combination of Topotecan and Taxotere in the second-line setting may prove promising in patients initially treated with paclitaxel and platinum-based therapy.
Topotecan and Taxotere have known activity in ovarian cancer patients. Recent weekly dosing schedules suggest similar activity in ovarian cancer patients with less toxicity. Ovarian cancer patients who have significant Taxane-related side effects, including neuropathy, do well with weekly Taxotere. Both Topotecan and Taxotere have documented efficacy in recurrent endometrial cancer, but no study, to date, has utilized them in combination for the treatment of endometrial cancer. In addition to utilizing this regimen in a phase II setting for recurrent ovarian cancer, we propose a phase II trial utilizing this combination for the treatment of recurrent endometrial cancer. The justification for including all of these tumor types in the same protocol is the known similar response rates of these Gynecologic tumors to all chemotherapies. The endpoints and power are designed for all of the histologic types, but subset analysis will be used for each tumor type after completion of the trial.
Because of the broad spectrum of antitumor activity of both Topotecan and Taxotere, several phase I/II trials have been conducted with this combination regimen. Lu and colleagues at MD Anderson administered docetaxel (Taxotere) intravenously on Day 1 followed by bolus daily intravenous Topotecan on days 1-3 with subcutaneous Neupogen (Filgrastim) support on days 4-13. Dose limiting toxicity for the regimen was febrile neutropenia, and the recommended dose for phase II trials was docetaxel 75 mg/m2 IV on day 1 and topotecan 1.4 mg/m2 IV on days 1-3 with Neupogen (filgrastim) 5 mcg/kg/d SC on days 4-13. Three of the 11 patients enrolled experienced a response with the combination (1 CR and 1 PR in nasopharynx cancer and 1 PR in SCLC). Aijaz and colleagues at New York Medical Center conducted a similar pilot study in patients with recurrent ovarian and primary peritoneal cancer. In this trial, all of the patients received docetaxel 80 mg/m2 IV on day 1 and topotecan 1.0 mg/m2 IV on days 1-5. The patients also received Neupogen (filgrastim) 10-mcg/kg beginning on day 6 and continuing until the neutrophil count recovered to ≥ 10,000/mL. The regimen was relatively well tolerated, with neutropenia being the most frequently reported side effect. Preliminary antitumor activity was impressive, with 1 complete response, 4 partial responses, and 4 stable diseases reported among the twelve patients enrolled in the pilot study. A final phase I study combining topotecan and docetaxel was also conducted at The University of Wisconsin by Stella and colleagues. In this trial docetaxel was administered IV on day 1 followed by daily IV bolus Topotecan on days 1-5. In contrast to the previous studies, prophylactic growth factor support was not administered following chemotherapy administration. Because of significant myelosuppression at the initial dose level, the protocol was amended and the starting dose of Topotecan was reduced. As expected, the dose-limiting toxicity was myelosuppression consisting of both neutropenia and thrombocytopenia. The maximum tolerated dose for the combination regimen was docetaxel 60 mg/m2 IV on day 1 followed by Topotecan 0.75 mg/m2/d on days 1-5.
Recently, the combination of Topotecan and Taxotere has been used in a Phase I setting in platinum sensitive patients with recurrent ovarian and primary peritoneal cancers. Eleven patients have been treated to date with weekly docetaxel 30 mg/m2/wk plus topotecan 3.5 mg/m2/wk. Two patients were non-evaluable, one due to rapidly progressive disease and one due to noncompliance. Of the nine evaluable patients, five patients experienced dose-limiting toxicities as follows,
One additional patient is planned to complete this dose level, to provide 10 evaluable patients. Of the 36 patients receiving 76 cycles of therapy, myelosuppression was brief and reversible with no febrile neutropenia. Per verbal communication from Dr. Burris, the recommended phase II dose will be docetaxel 30 mg/m2/wk plus topotecan 3.5 mg/m2/wk on days 1, 8 and 15 every 28 days for minimally pretreated patients.
In addition to possible synergy with this combination of drugs in other tumor types, the weekly dosing may have a better safety profile. The dose-limiting toxicity for Topotecan when administered on a daily x 5-administration schedule is myelosuppression. However, when the drug is administered on a weekly administration schedule, the myelosuppression is ameliorated and is no longer dose limiting. Additionally, weekly docetaxel administration is gaining in popularity in the clinical arena due to the improved toxicity profile of the drug. The possibility of synergy with the improved safety profile secondary to weekly dosing makes this combined dosing regimen a rational possibility for this patient population.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2|
|Study Design ICMJE||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Intervention ICMJE||Drug: Topotecan and Taxotere|
|Study Arm (s)||Not Provided|
|Publications *||Gupta D, Owers RL, Kim M, Kuo DY, Huang GS, Shahabi S, Goldberg GL, Einstein MH. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol. 2009 Jun;113(3):327-30. doi: 10.1016/j.ygyno.2009.02.018.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||March 2007|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00231855|
|Other Study ID Numbers ICMJE||MMC-04-05-131|
|Has Data Monitoring Committee||Yes|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Mark H. Einstein, Montefiore Medical Center|
|Study Sponsor ICMJE||Montefiore Medical Center|
|Information Provided By||Montefiore Medical Center|
|Verification Date||April 2012|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP